What are the recommendations for a patient with a low Hepatitis B Surface Antibody (Anti-HBs) level of <3.5 mIU/mL, indicating immunity is inconsistent?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a patient with a low Hepatitis B Surface Antibody (Anti-HBs) level of <3.5 mIU/mL, a booster dose of the Hepatitis B vaccine is recommended, as this level indicates inadequate immunity. The standard adult booster is a single dose of 20 mcg (1.0 mL) administered intramuscularly in the deltoid muscle, as indicated in the study by 1. After receiving the booster, the patient should have their Anti-HBs level rechecked 1-2 months later to confirm an adequate immune response (levels ≥10 mIU/mL), as suggested by 1 and 1. If the antibody level remains below 10 mIU/mL after the booster, a complete revaccination series may be necessary, consisting of three doses given at 0,1, and 6 months, as recommended by 1 and 1. Some patients, particularly those who are immunocompromised, older, or have certain health conditions, may have a diminished response to the vaccine and might require higher dosages or additional doses, as noted in 1 and 1. The booster is necessary because adequate Anti-HBs levels (≥10 mIU/mL) are crucial for protection against Hepatitis B infection, as emphasized by 1, 1, and 1. When antibody levels fall below this threshold, the immune system may not mount a sufficient response if exposed to the virus, potentially leading to infection. Key considerations for the booster dose include:

  • Administering the booster dose as soon as possible after determining the low Anti-HBs level
  • Using a single-antigen HepB vaccine for the booster dose, as recommended by 1
  • Monitoring the patient's Anti-HBs level after the booster dose to ensure an adequate immune response
  • Considering a complete revaccination series if the patient's Anti-HBs level remains below 10 mIU/mL after the booster dose.

From the Research

Hepatitis B Surface Antibody (Anti-HBs) Level and Immunity

  • A low Hepatitis B Surface Antibody (Anti-HBs) level of <3.5 mIU/mL indicates immunity is inconsistent 2, 3, 4, 5, 6.
  • According to various studies, a level of anti-HBs greater than 10 mIU/mL is considered consistent with immunity 2, 3, 4, 5, 6.
  • Patients with anti-HBs levels between 0.0 and 10.0 mIU/mL may not have sufficient immunity against Hepatitis B 2, 3, 4, 5, 6.

Recommendations for Patients with Low Anti-HBs Levels

  • For patients with low anti-HBs levels, revaccination or booster shots may be necessary to achieve sufficient immunity 3, 4, 5, 6.
  • The response to vaccination can be influenced by factors such as age, with younger recipients having a greater chance of developing sufficient anti-HBs levels 2.
  • Regular monitoring of anti-HBs levels is recommended to determine the need for revaccination or booster shots 4, 5, 6.

Vaccination and Immunity

  • Hepatitis B vaccination can provide long-term immunity against the virus, with anti-HBs levels remaining elevated for more than 10 years in some cases 6.
  • The vaccination scheme typically consists of three doses, and a successful vaccination is indicated by an anti-HBs titer higher than 100 IU/L 6.
  • Excellent immune memory is formed after successful vaccination, providing protection against Hepatitis B for an extended period 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005

Research

[Hepatitis B vaccine: simple and effective].

Nederlands tijdschrift voor tandheelkunde, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.